Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 20Leukemia, Myeloid, Acute 8Recurrence 7Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma 3Thymoma 2Ovarian Neoplasms 2Carcinoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Richter's Transformation 1Rhabdoid Tumor 1Prostatic Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Melanoma 1MDS 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 241Rituximab 223Etoposide 138Filgrastim 113Vincristine 112Doxorubicin 104Prednisone 90Cytarabine 90Methotrexate 79fludarabine phosphate 77Radiotherapy 76Peripheral Blood Stem Cell Transplantation 71Melphalan 71Busulfan 60Tacrolimus 48Dexamethasone 48Mycophenolic Acid 46Carmustine 46Granulocyte Colony-Stimulating Factor 44fludarabine 43Antilymphocyte Serum 40Ifosfamide 38sargramostim 34Whole-Body Irradiation 34Cyclosporine 33Bortezomib 32Gemcitabine 30Methylprednisolone 27Bendamustine Hydrochloride 27Lenalidomide 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × selinexor × Clear all
NCT02436707 2026-04-20

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase 2 Active not recruiting
129 enrolled
Lymphoid

Lymphoma

NCT07002099 2025-06-03

Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

Second Affiliated Hospital of Soochow University

Phase 2 Recruiting
26 enrolled
Lymphoid

Lymphoma

NCT06573151 2024-08-27

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

Ruijin Hospital

Phase 2 Not yet recruiting
28 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡